Logo image
Conjunctival stromal tumor: Report of 2 new cases and review of the literature
Journal article   Peer reviewed

Conjunctival stromal tumor: Report of 2 new cases and review of the literature

J. Lam, A. Ang, T. Vermeulen and N.M. Ardakani
International Journal of Surgical Pathology
2020
url
Link to Published Version *Subscription may be requiredView

Abstract

Conjunctival stromal tumor (COST) is an emerging entity with only a limited number of cases reported in the literature. In this report, we describe 2 additional cases, review the accumulative clinical and histopathological features and expand on the immunophenotypic property of this entity. COST appears to have a sporadic presentation, affecting both sexes and patients of variable ethnicity and age group and predominantly occurring on the bulbar conjunctiva as a slow-growing asymptomatic or slightly tender mass-like lesion. Histopathologically, COST is characterized by singly dispersed spindle to round cells, often with some degree of degenerative nuclear atypia, within a myxomatous to collagenous stroma. Lesional cells are characteristically positive for CD34 and vimentin, negative for S100, SOX10 and STAT6 and show a normal pattern of staining with RB1 by immunohistochemistry. The reported cases to date have shown an indolent biological behavior, reliably treated by a complete surgical excision.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.118 Soft Tissue, Bone & Nerve Cancers
1.118.1488 Cardiac Tumors
Web Of Science research areas
Pathology
Surgery
ESI research areas
Clinical Medicine
Logo image